Raffaella De Maria

University of Turin
Country flagItaly

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (17)

Canine oral malignant melanoma (COMM) is the most common neoplasm in the oral cavity characterized by local invasiveness and high metastatic potential. Hypoxia represents a crucial feature of the solid tumor microenvironment promoting cancer progression and drug resistance. Hypoxia-inducible factor-1α (HIF-1α) and its downstream effectors, vascular endothelial growth factor A (VEGF-A), glucose transporter isoform 1 (GLUT1), C-X-C chemokine receptor type 4 (CXCR4), and carbonic anhydrase IX (CAIX), are the main regulators of the adaptive response to low oxygen availability. The prognostic value of these markers was evaluated in 36 COMMs using immunohistochemistry. In addition, the effects of cobalt chloride–mediated hypoxia were evaluated in 1 primary COMM cell line. HIF-1α expression was observed in the nucleus, and this localization correlated with the presence or enhanced expression of HIF-1α-regulated genes at the protein level. Multivariate analysis revealed that in dogs given chondroitin sulfate proteoglycan-4 ( CSPG4) DNA vaccine, COMMs expressing HIF-1α, VEGF-A, and CXCR4 were associated with shorter disease-free intervals (DFI) compared with tumors that were negative for these markers ( P = .03), suggesting hypoxia can influence immunotherapy response. Western blotting showed that, under chemically induced hypoxia, COMM cells accumulate HIF-1α and smaller amounts of CAIX. HIF-1α induction and stabilization triggered by hypoxia was corroborated by immunofluorescence, showing its nuclear translocation. These findings reinforce the role of an hypoxic microenvironment in tumor progression and patient outcome in COMM, as previously established in several human and canine cancers. In addition, hypoxic markers may represent promising prognostic markers, highlighting opportunities for their use in therapeutic strategies for COMMs.

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (13)

Luca Aresu

Full Professor

Università degli Studi di Torino

ITALY
View details

Giuseppe Sarli

University of Bologna

ITALY
View details

Federica Riccardo

Post-doctoral fellow, "Assegno di Ricerca" (AIRC Prof. F.Cavallo))

Università degli Studi di Torino

ITALY
View details

Leonardo Della Salda

Profesore Ordinario

Università degli Studi di Teramo

ITALY
View details

Davide Prosperi

Full Professor, Biochemistry

University of Milano-Bicocca

ITALY
View details

Ugo Ala

Associate Professor

University of Turin

ITALY
View details

Filippo Torrigiani

University of Padova

ITALY
View details

Paolo Buracco

Full professor of veterinary surgery

University of Turin

ITALY
View details

Cecilia Gola

-

UNITED KINGDOM
View details

Marcella Massimini

University of Teramo

ITALY
View details

Antonio De Leo

University of Bologna

ITALY
View details

LUISA VERA MUSCATELLO

University of Bologna

ITALY
View details

Laura CAVICCHIOLI

assistant professor

University of Padova

ITALY
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.